Aclarion, Inc., a healthcare technology company specializing in Magnetic Resonance Spectroscopy (MRS) for clinical treatments, has reported its financial results for the year ended December 31, 2023. The company experienced a net loss of $4,911,374, a decrease from the previous year's net loss of $7,068,593. Despite the losses, Aclarion raised approximately $3.0 million in a public offering and entered into an equity line agreement with White Lion Capital, LLC for up to $10 million. The funds are expected to support operations into the third quarter of 2024. Aclarion's common stock and warrants are traded on the Nasdaq under the symbols 'ACON' and 'ACONW,' respectively. The company also conducted a reverse stock split to reduce the number of outstanding shares and increase the per-share value. Aclarion continues to focus on commercializing its NOCISCAN platform and securing payer contracts for its technology.

Aclarion, Inc., a healthcare technology company specializing in Magnetic Resonance Spectroscopy (MRS) for clinical treatments, has reported its financial results for the year ended December 31, 2023. The company experienced a net loss of $4,911,374, a decrease from the previous year's net loss of $7,068,593. Despite the losses, Aclarion raised approximately $3.0 million in a public offering and entered into an equity line agreement with White Lion Capital, LLC for up to $10 million. The funds are expected to support operations into the third quarter of 2024. Aclarion's common stock and warrants are traded on the Nasdaq under the symbols 'ACON' and 'ACONW,' respectively. The company also conducted a reverse stock split to reduce the number of outstanding shares and increase the per-share value. Aclarion continues to focus on commercializing its NOCISCAN platform and securing payer contracts for its technology.